Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial

BACKGROUND: Ansofaxine (LY03005) extended-release tablet is a potential triple reuptake inhibitor of serotonin, norepinephrine, and dopamine. This study assessed the efficacy, safety, and appropriate dosage of ansofaxine for the treatment of major depressive disorder (MDD). METHODS: A multicenter, r...

Descripción completa

Detalles Bibliográficos
Autores principales: Mi, Weifeng, Yang, Fude, Li, Huafang, Xu, Xiufeng, Li, Lehua, Tan, Qingrong, Wang, Guoqiang, Zhang, Kerang, Tian, Feng, Luo, Jiong, Xia, Jielai, Yuan, Kai, Lu, Lin, Deng, Jiahui, Tian, Jingwei, Zhang, Hongyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Regular Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929756/
https://www.ncbi.nlm.nih.gov/pubmed/34747448
http://dx.doi.org/10.1093/ijnp/pyab074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929756/
https://www.ncbi.nlm.nih.gov/pubmed/34747448
http://dx.doi.org/10.1093/ijnp/pyab074

Ejemplares similares